Company:  SORRENTO THERAPEUTICS, IN ... (SRNE)
Form Type:  8-K
Filing Date:  6/12/2019 
CIK:  0000850261 
Address:  4955 DIRECTORS PLACE 
City, State, Zip:  SAN DIEGO, California 92121 
Telephone:  858-203-4100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.27  
Change: 
0.03 (1.34%)  
Trade Time: 
01:55 PM EST  
Market Cap: 
$297.32M
Trade SRNE now with 

© 2019  
Description of Business
Sorrento Therapeutics, Inc. (Nasdaq: SRNE), together with its subsidiaries (collectively, the "Company", "we", "us" and "our") is a clinical stage and commercial biopharma company focused on delivering innovative and clinically meaningful therapies to patients and their families, globally, to address unmet medical needs. We primarily focus on therapeutics areas in Immune-Oncology and Non-Opioid Pain Management. We also have programs assessing the use of our technologies and products in autoimmune, inflammatory and neurodegenerative diseases. At our core, we are an antibody-centric company and leverage our proprietary G-MAB(TM) library and targeted delivery modalities to generate the next generation of cancer therapeutics. Our fully human antibodies include PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2 and CD137 among others.
Register and access this filing in:     
  FORM 8-K
    SECTION 7 REGULATION FD
      Item 7.01. Regulation FD Disclosure.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURES
  EXHIBIT 99.1